Resources
Below are several resources you may find helpful as you learn more about our company and product. If you are looking for something specific, please contact us at info@sqinnovation.com.
Publications
January, 2024
Osmanska J, Brooksbank K, Docherty KF, Robertson S, Wetherall K, McConnachie A, Hu J, Gardner RS, Clark AL, Squire IB, Kalra PR, Jhund PS, Muntendam P, McMurray JJV, Petrie MC, Campbell RT.
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies.
Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):35-44. doi: 10.1093/ehjcvp/pvad073. PMID: 37804170; PMCID: PMC10766906.
May 2026
Campbell RT, Osmanska J, Docherty KF, Ahmed FZ, Clark AL, Clayton L, Cleland JGF, Critoph C, Dewhurst M, Hartshorne-Evans N, Gardner RS, Gatenby KV, Guha K, Kalra PR, Lees A, McConnachie A, Muntendam P, Mowat K, O’Donnell J, Placzek A, Ray R, Savage HO, Schiff R, Squire I, Wetherall K, Wong K, Wong C, McMurray JJV, Petrie MC.
SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure
Eur J Heart Fail. 2026 May 2;28(1):121-129. doi: 10.1093/ejhf/xuaf018. PMID: 41771109.
February, 2025
Osmanska J, Petrie MC, Docherty KF, Lee MMY, McMurray JJV, Campbell RT.
Subcutaneous furosemide in heart failure: a systematic review.
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):94-104. doi: 10.1093/ehjcvp/pvae083. PMID: 39520561; PMCID: PMC11805693.
Presentations
FDA Approval Webcast
Slides from Conference Call and Webcast on October 9, 2025 at 4:30pm ET
PODD 2025
Slides from PODD Presentation on October 27, 2025
Media
